Core Viewpoint - The announcement from Kelun Pharmaceutical indicates that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC) A166 (also known as Shutailai®) for the treatment of adult patients with HER2-positive breast cancer who have previously received one or more anti-HER2 therapies [2] Group 1 - The approved drug A166 targets the human epidermal growth factor receptor 2 (HER2) [2] - The indication for A166 is for patients with unresectable or metastatic HER2-positive breast cancer [2] - The approval is significant as it addresses a patient population that has limited treatment options after prior therapies [2]

Core Viewpoint - The approval of the antibody-drug conjugate (ADC) A166 (also known as 博度曲妥珠单抗) by the National Medical Products Administration (NMPA) for treating HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 therapies marks a significant advancement in the treatment landscape for this patient population [1]. Group 1: Drug Approval and Clinical Study - The NMPA has approved A166 for use in patients with unresectable or metastatic HER2-positive breast cancer who have previously undergone treatment with one or more anti-HER2 drugs [1]. - The approval is based on a multicenter, randomized, open-label, controlled Phase 3 study (KL166-III-06) that evaluated the efficacy and safety of A166 compared to T-DM1 in patients with HER2-positive unresectable or metastatic breast cancer [1]. - The interim analysis showed that A166 significantly improved progression-free survival (PFS) compared to T-DM1, with a notable trend towards improved overall survival (OS) [1]. Group 2: Future Research and Development - The company has initiated an open-label, multicenter Phase 2 clinical study of A166 for treating HER2-positive unresectable or metastatic breast cancer previously treated with topoisomerase inhibitor ADCs [2].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its innovative antibody-drug conjugate (ADC) 7MW4911, targeting CDH17, a promising therapeutic target in various gastrointestinal cancers [1] Group 1: Company Developments - The clinical trial approval for 7MW4911 marks a significant milestone for the company, showcasing its proprietary IDDC™ antibody conjugation technology platform [1] - 7MW4911 is designed to target calcium adhesion protein 17 (CDH17), which is overexpressed in colorectal, gastric, and pancreatic cancers, indicating its potential for precise intervention [1] Group 2: Industry Context - CDH17 has been validated as a potential therapeutic target across multiple cancer types through pan-cancer multi-omics studies, highlighting its relevance in oncology [1] - The expression of CDH17 is limited to the basolateral membrane of intestinal epithelial cells in normal tissues, but shows significant overexpression in malignant tumors, correlating with tumor invasion, metastasis, and poor prognosis [1]

Core Insights - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has achieved a milestone in its global Phase II/III clinical trial IZABRIGHT-Breast01, triggering a $250 million milestone payment from Bristol-Myers Squibb (BMS) [1][2] - The total potential transaction value of the collaboration with BMS could reach up to $8.4 billion, setting a record for single-drug licensing in the ADC field [2] Group 1 - The milestone payment is the largest disclosed for a single ADC asset in domestic innovative drug overseas transactions [1] - SystImmune, a wholly-owned subsidiary of the company, will receive the payment for overseas drug development [1] - The collaboration includes joint development and commercialization of the first-in-class EGFR×HER3 dual antibody ADC, iza-bren (BL-B01D1), which is currently in Phase III clinical trials [1][2] Group 2 - BMS will pay an initial $800 million, along with two $250 million milestone payments, with additional payments potentially reaching $7.1 billion based on development, registration, and sales milestones [2] - The company is conducting three global key registration studies for late-stage triple-negative breast cancer, EGFR-TKI resistant late-stage non-small cell lung cancer, and treated late-stage metastatic urothelial carcinoma [2] - The company plans to present safety and efficacy data for iza-bren in Western solid tumor patients at the upcoming ESMO conference on October 17 [2] Group 3 - The company has multiple innovative drugs in clinical research, including iza-bren (BL-B01D1) and T-Bren (BL-M07D1), with nearly 90 clinical trials ongoing globally [3] - The company's first ARC (antibody-radiolabeled conjugate) drug, BL-ARC001, has recently received clinical trial approval from the National Medical Products Administration [3] - The company aims to become a leading multinational corporation (MNC) in the oncology treatment field, focusing on global expansion [3]

Core Insights - The company Keren Biotechnology (06990.HK) has received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC) sac-TMT, targeting TROP2, for a third indication in treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) [1][2] Group 1 - The approval is based on a randomized, open-label, multi-center Phase III clinical study (OptiTROP-Lung04), which will be presented at the 2025 European Society for Medical Oncology (ESMO) conference [2] - The study evaluates the efficacy and safety of sac-TMT administered every two weeks at a dose of 5 mg/kg compared to pemetrexed combined with platinum-based therapy in patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who have failed EGFR-TKI treatment [2] - Sac-TMT is the first and only ADC to show significant overall survival (OS) benefits compared to standard platinum-based doublet chemotherapy in this patient population [1][2] Group 2 - In March 2025, sac-TMT was approved by NMPA for use in patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who have progressed after EGFR-TKI and platinum-based chemotherapy [2] - The single-agent therapy with sac-TMT significantly extends the overall survival of these patients compared to standard treatment [2] - Another Phase III registration study of sac-TMT combined with osimertinib as first-line treatment for EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC has completed patient enrollment in China [2]

科伦药业(002422.SZ)发布公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司 (简称"科伦博泰")靶向人滋养细胞表面抗原 2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT， 亦称SKB264/MK-2870)(佳泰莱®)获国家药品监督管理局(NMPA)批准第三项适应症，用于治疗经表皮生 长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞 状非小细胞肺癌(NSCLC)成人患者。 芦康沙妥珠单抗(sac-TMT)是迄今为止全球首个且唯一对比含铂双药化疗显示出显著的总生存期(OS)获 益，并且已获批用于仅接受过 TKI 治疗后进展(2L)的晚期NSCLC 的 ADC。在预设的 OS 期中分析中， 与目前含铂双药化疗标准治疗相比，芦康沙妥珠单抗(sac-TMT)单一疗法在无进展生存期和总生存期均 具有显著统计学意义和临床意义的改善，显著延长此类患者的无进展生存期和总生存期。 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its injectable HLX43, a targeted antibody-drug conjugate (ADC) developed in collaboration with a new DNA topoisomerase I inhibitor [1] Group 1 - The HLX43 is a conjugate of a newly licensed small molecule toxin-peptide chain and an independently developed PD-L1 targeting antibody [1]

Core Viewpoint - HengRui Medicine has signed a licensing agreement with Glenmark Specialty for the innovative drug SHR-A1811, expanding its market reach and enhancing its global presence in cancer treatment [1][3]. Group 1: Licensing Agreement Details - The agreement allows Glenmark Specialty to license SHR-A1811, an antibody-drug conjugate targeting HER2, which is designed to induce apoptosis in tumor cells [1]. - Glenmark Specialty will pay an upfront fee of $18 million to HengRui, with potential milestone payments related to registration and sales reaching up to $1.093 billion [2]. Group 2: Clinical Development and Approvals - SHR-A1811 has received approval for use in adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations, marking it as the first Chinese-developed ADC for this indication [1]. - Multiple clinical studies are ongoing, with SHR-A1811 receiving orphan drug designation from the FDA for use in gastric cancer and related conditions, and a new indication for breast cancer under priority review by the National Medical Products Administration [2]. Group 3: Strategic Implications - The agreement is expected to broaden the overseas market for SHR-A1811, providing high-quality treatment options for global patients and enhancing HengRui's innovative brand and international performance [3]. - The company aims to strengthen international cooperation while maintaining a focus on independent research and development, facilitating rapid transformation of research outcomes into marketable products [3].

Group 1 - The core message is that Baiaosaitu (02315.HK) has made significant progress with its cancer treatment drug IDE034, which is being developed in collaboration with IDEAYA Biosciences, and plans to submit a clinical trial application to U.S. regulators in Q4 2024 [1][2] - IDE034 is an antibody-drug conjugate (ADC) designed to target two tumor markers, B7H3 and PTK7, and is based on Baiaosaitu's BLD1102 technology [1] - The potential transaction value for the licensing agreement with IDEAYA is close to 3 billion RMB, and if successful, IDE034 could become the first ADC product in the dual-target field to enter clinical stages [1] Group 2 - In terms of international collaboration, Baiaosaitu has partnered with companies such as SOTIO, ABL Bio, Radiance, and ADC Therapeutics in the dual-target ADC field [2] - Financial data shows that Baiaosaitu achieved a revenue of 621 million RMB in the first half of 2025, representing a year-on-year growth of 51.3%, with nearly 70% of revenue coming from overseas collaborations [2] - The company has filed 496 patent applications and signed 80 new licensing agreements, marking a 60% increase year-on-year [2]

Core Insights - The 2025 World Lung Cancer Conference showcased significant advancements in innovative drugs from Chinese pharmaceutical companies, highlighting the increasing international recognition of Chinese innovation in the pharmaceutical sector [1][2]. Group 1: Company Achievements - Sichuan BaiLi TianHeng Pharmaceutical Co., Ltd. presented its groundbreaking EGFR×HER3 dual antibody ADC, iza-bren, which is the first of its kind to enter Phase III clinical trials globally [1][3]. - The clinical trials for iza-bren demonstrated a tumor shrinkage rate of 94% in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), significantly outperforming existing treatments [2][3]. - BaiLi TianHeng has established a global strategic partnership with Bristol-Myers Squibb, with a total deal value of up to $8.4 billion, marking iza-bren as the first Chinese dual antibody ADC to enter international markets [4]. Group 2: Industry Trends - The number of approved innovative drugs in China has steadily increased, with 197 innovative drugs approved from 2018 to 2024, and the annual approval rate rising from 11 in 2018 to 48 in 2024 [3]. - Over 120 Chinese pharmaceutical companies are engaged in ADC research, contributing to a global pipeline of over 600 projects [2][3]. - The Chinese biopharmaceutical sector benefits from a growing number of biotech companies, a robust clinical research infrastructure, and an evolving regulatory environment that enhances the speed of drug approvals [6].